logo

A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder.

This page provides detailed information about this publication. Please click on any text which is underlined to find more information.


Authors
Daniel Umbricht, Marta del Valle Rubido, Eric Hollander, James T. McCracken, Frederick Shic, Lawrence Scahill, Jana Noeldeke, Lauren Boak, Omar Khwaja, Lisa Squassante, Christophe Grundschober, Heidemarie Kletzl, Paulo Fontoura
Title
A single dose, randomized, controlled proof-of-mechanism study of a novel vasopressin 1a receptor antagonist (RG7713) in high-functioning adults with autism spectrum disorder.
Journal
Neuropsychopharmacology
Year
2016
Abstract Link
Read Abstract (New Window)
Publication Format
Journal Article
Efficacy Study/Review
Yes
Scientific Validity
Peer-Reviewed, Randomised Trial, Controlled Trial, Multisite, Double Blind, Placebo
Comments
ClinicalTrials.gov identifier: NCT01474278
Keywords
Adult, Autism, Autistic Disorder, Communication Skills, High Functioning, Intervention, Medication, RG7713, Social Skills, Vasopressin 1a Receptor Antagonist

Please note that we are unable to supply publications unless we are listed as the publisher. However, if you are a UK resident you may be able to obtain them from your local public library, your college library or direct from the publisher.


Publications | Publications Database | Search Publications